Asia Pac Allergy:永久性过敏性鼻炎患者中,血清25-羟甲基维生素D与血嗜酸细胞负相关

2017-11-09 AlexYang MedSci原创

维生素D和过敏性鼻炎(AR)之间的关系仍旧不清楚。最近,有研究人员通过在患有AR的病人中检测血清25-羟甲基维生素D(25(OH)D)调水平、血嗜酸细胞和维生素D受体(VDR)在鼻粘膜上的表达调查了它们之间的关系。研究包括了32名患有永久性过敏性鼻炎的病人和25名对照。研究人员通过酶联免疫试验检测了血清25(OH)D的水平,利用自动化的血液系统检测了外周血嗜酸细胞,然而在下鼻甲粘膜中VDR的表达则

维生素D和过敏性鼻炎(AR)之间的关系仍旧不清楚。最近,有研究人员通过在患有AR的病人中检测血清25-羟甲基维生素D(25(OH)D)调水平、血嗜酸细胞和维生素D受体(VDR)在鼻粘膜上的表达调查了它们之间的关系。

研究包括了32名患有永久性过敏性鼻炎的病人和25名对照。研究人员通过酶联免疫试验检测了血清25(OH)D的水平,利用自动化的血液系统检测了外周血嗜酸细胞,然而在下鼻甲粘膜中VDR的表达则是通过免疫组化技术进行评估。更多的是,研究人员还分析了AR中的血清25(OH)D水平和血嗜酸细胞水平之间的关系。

研究发现,在AR组和对照组中,血清25(OH)D水平在并没有显著的差异(p=0.371)。有趣的是,AR组中血清25(OH)D的水平与血嗜酸细胞数目和它的比例呈现负相关关系(分别为p=0.019和p=0.010),甚至是在调整了混杂因素包括年龄、性别、身体质量指数和采血季节后上述负相关关系仍旧存在。另一方面,鼻粘膜VDR的表达水平在AR组和对照组中没有发现显著差异(p=0.231)。最后,研究人员指出,这些结果表明了在永久性AR中,血清25(OH)D也许与血嗜酸细胞成负相关关系。然而,维生素D和AR之间的关系仍旧需要进一步的分析。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780077, encodeId=9b9e1e8007769, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 13 12:00:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046896, encodeId=f6542046896c1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Apr 02 14:00:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329030, encodeId=d3901329030f5, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573227, encodeId=093a15e3227eb, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260291, encodeId=1289260291f5, content=学习了.非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Nov 10 15:31:02 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260084, encodeId=3956260084e8, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Nov 09 21:43:39 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2018-07-13 luwei00
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780077, encodeId=9b9e1e8007769, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 13 12:00:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046896, encodeId=f6542046896c1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Apr 02 14:00:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329030, encodeId=d3901329030f5, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573227, encodeId=093a15e3227eb, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260291, encodeId=1289260291f5, content=学习了.非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Nov 10 15:31:02 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260084, encodeId=3956260084e8, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Nov 09 21:43:39 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780077, encodeId=9b9e1e8007769, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 13 12:00:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046896, encodeId=f6542046896c1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Apr 02 14:00:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329030, encodeId=d3901329030f5, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573227, encodeId=093a15e3227eb, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260291, encodeId=1289260291f5, content=学习了.非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Nov 10 15:31:02 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260084, encodeId=3956260084e8, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Nov 09 21:43:39 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2017-11-11 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780077, encodeId=9b9e1e8007769, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 13 12:00:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046896, encodeId=f6542046896c1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Apr 02 14:00:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329030, encodeId=d3901329030f5, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573227, encodeId=093a15e3227eb, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260291, encodeId=1289260291f5, content=学习了.非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Nov 10 15:31:02 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260084, encodeId=3956260084e8, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Nov 09 21:43:39 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2017-11-11 hmwwww
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780077, encodeId=9b9e1e8007769, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 13 12:00:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046896, encodeId=f6542046896c1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Apr 02 14:00:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329030, encodeId=d3901329030f5, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573227, encodeId=093a15e3227eb, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260291, encodeId=1289260291f5, content=学习了.非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Nov 10 15:31:02 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260084, encodeId=3956260084e8, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Nov 09 21:43:39 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2017-11-10 天涯183

    学习了.非常好的文章

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1780077, encodeId=9b9e1e8007769, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Fri Jul 13 12:00:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046896, encodeId=f6542046896c1, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Apr 02 14:00:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329030, encodeId=d3901329030f5, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573227, encodeId=093a15e3227eb, content=<a href='/topic/show?id=34009226531' target=_blank style='color:#2F92EE;'>#负相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92265, encryptionId=34009226531, topicName=负相关)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c2115837741, createdName=hmwwww, createdTime=Sat Nov 11 12:00:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260291, encodeId=1289260291f5, content=学习了.非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Nov 10 15:31:02 CST 2017, time=2017-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260084, encodeId=3956260084e8, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Nov 09 21:43:39 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2017-11-09 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Nat Genet:哮喘、枯草热和湿疹共有的遗传起源阐释了过敏疾病生物学

哮喘、枯草热(或者过敏性鼻炎)和湿疹(或者过敏性皮肤炎)经常在同一个个体中同时存在,可能的原因部分的归结于共享的遗传起源。最近,有研究人员为了鉴定共有的风险变异,进行了广泛的过敏性疾病表型的全基因组关联研究(GWAS;n=360838),上述三种疾病中,任何一种的出现均包含在研究中。研究鉴定了136个独立的风险变异(P < 3 × 10-8),包括了73个之前未报道的变异,而这些未报道的变异

Int Arch Otorhinolaryngol:过敏性鼻炎儿科病人生活质量分析

过敏性鼻炎是一种在儿童和青少年中常见的疾病,达到了该人群人口数目的40%。在儿童时期,人们通常不会进行过敏性鼻炎诊断,因为它并没有表现出特异的症状。过敏性鼻炎对生活质量具有消极影响并且也许引起各种并发症。诊断是临床性质的并且治疗的目的是预防。最近,有研究人员评估了儿科病人中患有过敏性鼻炎儿童的生活质量。该研究是一个观察性质的代表性研究。研究群体包括患有过敏性鼻炎的儿科病人,并且他们在巴西的圣卡塔琳

J Immunol:过敏性鼻炎患者鼻过敏原挑战外周血免疫基因特性调查

鼻过敏原挑战(NAC)是过敏性鼻炎(AR)的一种人类模型,具体是通过局部地接种标准的过敏原到鼻粘膜上,从而引起临床症状以及生物样本的搜集,比如外周血的搜集。尽管许多研究集中在了局部炎症位点,一个重要的调控子和系统免疫响应的成员-外周血在AR中却并没有很好的研究。最近,有研究人员调查了在患有AR的病人经历NAC之后,外周血中免疫基因的特性。研究人员在NAC处理期间搜集了临床症状信息和外周血样本,并利

Rhinology:P-AzeFlu可以快速和有效的控制过敏性鼻炎

过敏性鼻炎和它对哮喘的影响(ARIA)以及欧盟(EU)推荐了指导过敏性鼻炎(AR)治疗选定的改变,即从症状反应到疾病控制,并使用了一个简单的视觉模拟评分体系(VAS)。最近,有研究人员利用VAS评估了MP-AzeFlu鼻用喷雾在罗马尼亚现实研究中的效果。在该多中心,前瞻性和非干预性研究中,253名(大于11岁)患有中等程度到重度AR的病人进行了MP-AzeFlu治疗,并且研究人员利用VAS(从0-

Clin Immunol:过敏性鼻炎患者对屋尘螨增加的先天2型免疫响应

2型先天淋巴样细胞(ILC2s)在起始和促进过敏免疫响应中是必要的成员。然而,研究人员在探究过程中发现了ILC2水平的过敏性鼻炎(AR)患者中的不一致性。最近,有研究人员调查了ILC2在屋尘螨(HDM)过敏性AR病人外周血中的水平,并且还调查了他们分泌2型细胞激素的能力。研究发现,ILC2s且具有ILC2表型特性的水平在HDM-AR病人中增加。AR病人的症状得分和IL-13的水平与HDM-AR病人

Health Qual Life Outcomes:屋尘螨和花粉过敏性鼻炎病人舌下免疫治疗生活品质的改善研究

过敏性鼻炎具有较高的流行度,并且它的负担对病人的日常生活品质造成了严重的影响。过敏性鼻炎与日常活动、工作、学习以及现实问题的干扰有关。并且,病人还要承受睡眠障碍和情绪问题。舌下免疫治疗在生活品质方面的优势最近才得以重视。最近,有研究人员进行了前瞻性的现实生活研究,旨在评估为期3年的舌下免疫治疗对屋尘螨(HDM)花粉提取物过敏成年人的生活品质的影响。研究包括了191名成年人(105名男性;平均年龄为